Inhibition of platelet factor 3 availability by prostacyclin

Prostaglandins
J HársfalviL Fésüs

Abstract

Preincubation of human platelet rich plasma with PGI2 in a concentration preventing collagen induced platelet aggregation abolished also platelet factor 3 availability brought about by collagen. Following PGI2 pretreatment no second wave aggregation could be elicited by ristocetin. However, primary aggregation as well as platelet factor 3 activity were only partially inhibited in this case and the inhibitory action of PGI2 was not increased by raising its concentration. Similarly, marked but not complete inhibition of platelet factor 3 availability was obtained when kaolin was used as activating agent.

References

Jul 1, 1987·Thrombosis Research·J SkopálG Kovács
Mar 15, 1990·Thrombosis Research·M MahafzahJ L Ambrus

Citations

Nov 18, 1978·Lancet·H F WoodsJ R Vane
Sep 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·B B WekslerE A Jaffe
Oct 15, 1978·Experientia·R Gryglewski, K C Nicolaou
Jan 1, 1979·Haemostasis·S Moncada, J L Amezcua
Sep 1, 1979·British Journal of Haematology·M D Schneider-TripJ W ten Cate
Nov 1, 1966·British Journal of Haematology·R M Hardisty, R A Hutton
May 1, 1965·British Journal of Haematology·T H SPAET, J CINTRON

Related Concepts

Aggregation
Flolan
Ristomycin
Platelet Factor 3
Zyderm
Epoprostenol
Platelet Aggregation
Metabolic Inhibition
Blood Coagulation Factor
Collagen Location

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.